Regencell Bioscience Holdings Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Regencell Bioscience Holdings Limited generated cash of -$4,001,687, which is more than the previous year. Cash used in financing activities reached the amount of $102,282 last year. Net change in cash is therefore $1,396,440.
Cash Flow
| 2012 | 346.6M | 69.6M | -306.7M |
|---|---|---|---|
| 2013 | 346.9M | -149.2M | 83.2M |
| 2015 | 349.1M | 130.4M | -332.4M |
| 2016 | 410.5M | -223.6M | -160M |
| 2019 | -390.99K | 0 | 480.99K |
| 2020 | -726.57K | -117.83K | 988.08K |
| 2021 | -767.31K | 0 | 439.74K |
| 2022 | -5.26M | -10.78M | 22.40M |
| 2023 | -4.96M | 58.97K | 134.91K |
| 2024 | -4.00M | 5.24M | 102.28K |
RGC Cash Flow Statement (2013 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2015 | 2013 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.56M | 6.41M | 59.41K | 386.97K | 243.30K | 153.30K | 219.6M | 280M | 109M | 253M |
Operating activities | ||||||||||
Net income | -4.36M | -6.06M | -7.59M | -1.34M | -812.37K | -390.99K | 170.4M | 105.6M | 157.7M | 144.8M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 745.58K | 769.68K | 604.39K | 26.45K | 9.51K | 0 | 230.7M | 212M | 204.5M | 186.2M |
Stock-based compensation expense | 449.31K | 922.62K | 2.75M | 0 | 0 | 0 | 0 | 0 | 9.3M | 10.3M |
| Deferred income tax benefit | 449.31K | 922.62K | 2.75M | 0 | 0 | 0 | 0 | 0 | 9.3M | 10.3M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | -7M | -4M | -12M | -3M |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 1.5M | 1.3M | -100K | -2.7M |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | -38.3M | -200K | 2M | -22.9M |
Cash generated by operating activities | -4.00M | -4.96M | -5.26M | -767.31K | -726.57K | -390.99K | 410.5M | 349.1M | 346.9M | 346.6M |
Investing activities | ||||||||||
Purchases Of Investments | -5M | -10M | -10M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -5.37K | -27.39K | -780.87K | 0 | -117.83K | 0 | -214.9M | -156.8M | -112.1M | -89.2M |
Acquisitions Net | 0 | 970 | 0 | 0 | 0 | 0 | 0 | 0 | -194.4M | -89.7M |
Cash generated by investing activities | 5.24M | 58.97K | -10.78M | 0 | -117.83K | 0 | -223.6M | 130.4M | -149.2M | 69.6M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 22.67M | 0 | 0 | 0 | 0 | 0 | 40M | 92M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -132.2M | -287.3M |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -147.1M | -280.9M | -109.5M |
Repayments of term debt | 0 | 0 | 0 | -612.05K | -988.08K | 480.99K | 0 | 0 | -13.5M | -46M |
Cash used in financing activities | 102.28K | 134.91K | 22.40M | 439.74K | 988.08K | 480.99K | -160M | -332.4M | 83.2M | -306.7M |
Net Change In Cash | 1.39M | -4.85M | 6.35M | -327.56K | 143.67K | 90.00K | 26.9M | -132.9M | 171.9M | -143.5M |
Cash at end of period | 2.96M | 1.56M | 6.41M | 59.41K | 386.97K | 243.30K | 246.5M | 147.1M | 280.9M | 109.5M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |